Australia's most trusted
source of pharma news
Thursday, 25 April 2024
Posted 30 May 2022 AM
Nearly all drug applications accepted by the TGA from April to May were for new indications with AbbVie leading the pack.
The regulator accepted new indications for two drugs from AbbVie's immunology franchise, which have both already been submitted under parallel processing to the PBAC's next big meeting in July.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.